In his weekly clinical update, Dr. Griffin discusses the CDC vaccine advisory group recommending the newly approved RSV vaccines, association of culturable-virus detection and household transmission of SARS-CoV-2, prevention of COVID-19 following a single intramuscular administration of Adintrevimab, real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19, and COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization.
Click arrow to play Download TWiV 1018 (24 MB .mp3, 39 min)
Vincent travels to the University of Pennsylvania to meet up with Susan, Rick, Gigi and David to discuss the origin of SARS-CoV-2, how the FBI might have reached its conclusion on the matter, and public and political perception of scientific risk.
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.
Click arrow to play Download TWiV 1016 (31 MB .mp3, 52 min)
Vincent and Rich travel to Ft. Detrick to visit USAMRIID and speak with Todd, Crystal, John and Jay about their careers, their research, and the mission of the US Army Medical Institute of Infectious Diseases.
Opinions, interpretations, conclusions, and recommendations are those of the panelists and no official endorsement by the U.S. Army should be inferred.
In his weekly clinical update, Dr. Griffin discusses estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status, smart thermometer–based participatory surveillance to discern the role of children in household viral transmission during the COVID-19 pandemic, COVID-19 vaccine mandates, changing severity and epidemiology of adults hospitalized with COVID-19 in the United States after introduction of COVID-19 vaccines, effectiveness of COVID-19 treatment with Nirmatrelvir–Ritonavir or Molnupiravir among U.S. veterans, national trends in anticoagulation therapy for COVID-19 hospitalized adults in the United States, development of a definition of postacute sequelae of SARS-CoV-2 infection, neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms, long COVID clinical phenotypes up to six months after infection identified by latent class analysis of self-reported symptoms, and coronary microvascular health in symptomatic patients with prior COVID-19 infection.
Click arrow to play Download TWiV 1014 (24 MB .mp3, 40 min)
TWiV reviews remarkable changes in the epidemiology of avian H5N1 influenza virus leading to previously uninfected areas, involvement of previously unaffected wild birds, and devastating outbreaks in farmed poultry, and isolation of a monoclonal antibody against the influenza virus neuraminidase that inhibits infection with a wide range of A and B isolates.
In his weekly clinical update, Dr. Griffin discusses the potential for recurrent Mpox outbreaks among gay, bisexual, and other men who have sex with men, association between SARS-CoV-2 variants and frequency of acute symptoms, prospective study of key correlates for household transmission of SARS-CoV-2, Pfizer’s PAXLOVID™ receiving FDA approval for adult patients at high risk of progression to severe COVID-19, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, development of a definition of postacute sequelae of SARS-CoV-2 infection, COVID-19 and risk for mental disorders among adults in Denmark, risk of new post-COVID mental disorders higher only in older patients.
Click arrow to play Download TWiV 1012 (23 MB .mp3, 38 min)
Vincent travels to Québec City, Canada and the 11th Aquatic Virus Workshop, where he speaks with Fred Aylward and Jed Furman about the research of their laboratories on the ecology and evolution of aquatic viruses and their microbial communities.
In his weekly clinical update, Dr. Griffin discusses the CDC HIV surveillance report, FDA voted in favor of approving the Abrysvo vaccine, canine olfactory detection of SARS-CoV-2-infected humans, safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years, and statement on the antigen composition of COVID-19 vaccines.
Click arrow to play Download TWiV 1010 (21 MB .mp3, 36 min)
Vincent travels to Montreux, Switzerland and the 16th International Nidovirus Symposium, where he speaks with Maria von Kerkhove, the face of COVID-19 for the World Health Organization, and Kanta Subbarao, Director of the WHO Collaborating Centre on Influenza in Melbourne.
